

# Clinical Practice and Patient Burden Associated with Anti-Seizure Medication Titration: A Thematic Analysis

John M. Stern,<sup>1</sup> Danielle A. Becker,<sup>2</sup> Steve S. Chung,<sup>3</sup> Micheal Macken,<sup>4</sup> David King-Stephens,<sup>5</sup> Andrew J. Zillgitt,<sup>6</sup> Mohamad Z. Koubeissi<sup>7</sup>

<sup>1</sup>Department of Neurology, UCLA School of Medicine <sup>2</sup>Department of Neurology, The Ohio State University Wexner Medical Center <sup>3</sup>University of Arizona, Banner–University Medical Center <sup>4</sup>Northwestern University Feinberg School of Medicine <sup>5</sup>Department of Neurology, University of California Irvine <sup>6</sup>Department of Neurology, Corewell Health William Beaumont University Hospital Neuroscience Center <sup>7</sup>Department of Neurology, George Washington University

## RATIONALE

- Epileptic seizures are classified by onset and clinical presentation, including focal, generalized, unknown (whether focal or generalized), and unclassified.<sup>1</sup> Of these, focal seizures (FS) account for approximately 60% of the ~3 million adults with epilepsy in the U.S.<sup>2,3</sup>
- Most anti-seizure medications (ASMs) recommend slow titration to improve tolerability, potentially delaying therapeutic dosing and optimal seizure control.<sup>4</sup> The titration of ASMs for FS can take months, and patients may struggle with complex titration schedules<sup>5</sup>
- While ASMs include FDA-recommended titration instructions, the titration process is often individualized on various factors including patient characteristics and ASM-specific factors<sup>4,5</sup>
- Although the challenges of ASM titration have been described, there remains a gap in understanding how patients with FS and healthcare providers (HCPs) experience this process in real-world practice

## OBJECTIVE

- To assess both patient and HCP perspectives on the practical realities of ASM titration, focusing on identifying key unmet needs and defining the burden on both patients with FS and HCPs who directly treat these patients

## METHODS

### Participants: Patients with FS

- A cross-sectional, web-based survey was conducted in January 2025 among patients with a physician-confirmed diagnosis of FS the study was approved by an institutional review board (IRB) (WCG IRB, Cary, NC)
- Participants completed a screening survey and were eligible if they had tried and failed ≥1 ASM within the past year and either (a) had both an office visit and used an ASM requiring titration and/or dose escalation/modification\* within the past year, or (b) were currently using or initiating an ASM requiring titration and/or dose escalation/modification and had no history of psychogenic non-epileptic seizures, Dravet syndrome, Lennox–Gastaut syndrome, or other developmental and epileptic encephalopathies
- Data collected included demographics, clinical history, and epilepsy-specific quality-of-life measures. The survey also assessed factors influencing ASM selection, adherence, side effects, dose modifications, healthcare resource utilization (HCRU), challenges and emotions experienced during titration
- Outcomes were summarized using descriptive statistics, including means and standard deviations (SDs) for continuous variables and frequency counts and percentages for categorical variables

### Participants: Physician Experts

- A moderated physician roundtable was conducted in April 2025 among U.S. board-certified physicians (MD/DO) who treat patients with FS and met the following eligibility criteria: manage ≥25 FS patients per month (with ≥50% initiating or undergoing ASM titration or dose escalation/modification\*) currently manage ≥5 patients meeting the patient-survey inclusion criteria have current or prior experience prescribing titration-requiring ASMs and are willing and able to complete a 30-minute interview on ASM switching and outcomes
- Prior to the roundtable discussion, each physician participated in a 30-minute, semi-structured interview about their practices and perspectives across the titration process, including initial dosing strategies, monitoring techniques, adherence to prescribing guidelines, and challenges with drug–drug interactions (DDIs)
- Data from the patient survey and physician interviews informed the roundtable agenda and discussion topics
- The roundtable discussion was transcribed and analyzed using thematic analysis; analysts independently coded the transcript, reconciled discrepancies by consensus, and organized salient themes

\*Dose escalation/modification is considered different than titration, which is FDA-recommended to reach therapeutic dosing. Dose escalation/modification could be 1) increasing the dose after reaching a therapeutic dose, 2) reducing the dose over time, or 3) cross-titration which means decreasing the dose of one drug while simultaneously increasing the dose of another drug.<sup>6</sup>

## RESULTS

### Participants: Patients with FS

- Demographic characteristics of the surveyed patients with FS (N=48) are summarized in **Table 1**

**Table 1. Patient Characteristics**

	(N=48)
<b>Age (N=45)<sup>a</sup></b>	
Mean (SD)	35 (13)
Median (Range)	32 (19–70)
<b>Sex, n (%)</b>	
Female	21 (44)
Male	27 (56)
<b>Ethnicity, n (%)<sup>b</sup></b>	
White	20 (42)
Hispanic or Latino	13 (27)
Black or African American	9 (19)
Asian / Pacific Islander	5 (10)
Native American or American Indian	1 (2)
<b>Age at diagnosis of epilepsy (N=45)<sup>a</sup></b>	
Mean (SD)	24 (16)
Median (Range)	22 (0–65)

SD=standard deviation

<sup>a</sup>Data regarding age and age at diagnosis of epilepsy are missing for n=3 patients.

<sup>b</sup>Respondents were able to select all response options that applied therefore, the responses are not mutually exclusive.

### Participants: Physician Experts

- Characteristics of participating physicians (N=7) are summarized in **Table 2** all were epileptologists treating a mean of 95 FS patients per month

**Table 2. Physician Expert Characteristics**


	(N=7)
<b>Primary specialty, n (%)</b>	
Epileptologist	7 (100)
<b>Setting of practice, n (%)</b>	
Academic medical hospital	7 (100)
<b>Years in practice since completing their education</b>	
Mean (SD)	20 (7)
Median (Range)	25 (10–26)
<b>Patients with FS treated per month</b>	
Mean (SD)	95 (21)
Median (Range)	100 (70–120)

FS=focal seizures SD=standard deviation

### Thematic Analysis

- The main theme and emerging subthemes from the roundtable are shown in **Figure 1**


**Figure 1. Main Theme and Subthemes Emerging from the Roundtable**



### Greater Complexity of Clinical Management

- Physicians reported that cross-titration, the process of decreasing the dose of one drug while simultaneously increasing the dose of another drug when switching between medications or initiating combination therapy, is largely guided by expert consensus and associated with unpredictable outcomes
- During cross-titration, physicians shared that they balance multiple, often competing considerations, including DDIs that add complexity, particularly when complications arise (**Figure 2**)
- Physicians also reported that complex dosing schedules (e.g., multiple daily administrations and variable day-to-day doses) can negatively impact adherence


**Figure 2. Cross-Titration Considerations**



DDI=drug–drug interactions PD=pharmacodynamics PK=pharmacokinetics

- Patients with FS reported concerns they experienced during the titration of their ASM, including worry about having focal seizures during the titration process (56%) and not having a clear understanding of the titration process (35%) (**Figure 3**)

**Figure 3. Patient-Reported Concerns Experienced During Titration (N=48)**




<sup>a</sup> Respondents were able to select all response options that applied therefore, the responses are not mutually exclusive.

**Question:** During the titration (the time when your doctor gradually adjusts your medication dose to find the right amount that works best for you) of [index ASM], did you have any of the following **concerns**? Please select all that apply.

- Patients with FS also reported that the time and number of clinic visits/phone calls needed to reach the target dose (60%) and keeping up with multiple ASM dose adjustments (44%) were challenges they encountered during ASM titration (**Figure 4**)

**Figure 4. Patient-Reported Challenges Encountered During Titration (N=48)**



ASM=anti-seizure medication


<sup>a</sup> Respondents were able to select all response options that applied therefore, the responses are not mutually exclusive.

**Question:** During the titration (the time when your doctor gradually adjusts your medication dose to find the right amount that works best for you) of [the index ASM], what **challenges** did you face, if any? Please select all that apply.

### Increased Strain on Healthcare Resources

- Physicians reported that ASM titration is associated with increased HCRU, spanning both quantifiable events (e.g., emergency department visits) and less easily measured burden (e.g., communication workload)
- During titration, physicians identified the following increases in HCRU (**Figure 5**):
  - Increased reliance on clinic staff to triage calls and provide patient support
  - Higher volume of patient communication (emails and portal messages)
  - More frequent follow-up clinic visits to monitor patients during titration
  - Additional time spent developing/updating titration schedules and educational materials
  - Greater coordination with pharmacists to convey titration instructions and confirm prescriptions


**Figure 5. Physician Expert Reports of Increased HCRU Related to Titration**



### Underrecognized Burden of Titration

- Physicians previously viewed titration as routine and may not have fully appreciated the challenges experienced by patients and non-specialist HCPs. All (100%) agreed that the burden of titration is greater than what is generally recognized (**Figure 6**)
- Patient-reported data were consistent with physician observations that titration burden may be underrecognized during titration; patients worried about breakthrough seizures (**Figure 3**) and reported difficulty keeping up with ASM dose adjustments and understanding the titration steps (**Figure 4**)

**Figure 6. Physician Expert Insights on the Burden of Titration**



## CONCLUSIONS

- This patient and physician research revealed titration is rarely part of the dialogue among physicians, despite titration's effect on clinical management complexity and increased strain on healthcare resources
- These findings underscore the substantial and potentially overlooked burden associated with ASM titration on patients and physicians, highlighting the need for improved communication between patients and physicians, as well as the need for ASMs that require simplified or no titration
- Increasing awareness of the burden of titration within the wider epilepsy community may improve shared decision-making through recognition of titration-related factors that may negatively impact the patient experience with ASMs

## References

- Beniczky S, Trinka E, Wirrell E et al. Updated classification of epileptic seizures: Position paper of the International League Against Epilepsy. *Epilepsia*. 2025 Jun;66(6):1804-1823. doi: 10.1111/epi.18338
- Gupta S, Rhylin P, Faught E, Tsong W, Kwan P. Understanding the burden of focal epilepsy as a function of seizure frequency in the United States, Europe, and Brazil. *Epilepsia Open*. 2017;2(2):199-213. Published 2017 Mar 27. doi:10.1002/epid.12050
- Zack MM, Kobau R. National and State Estimates of the Numbers of Adults and Children with Active Epilepsy - United States, 2015. *MMWR Morb Mortal Wkly Rep*. 2017;66(31):821-825. Published 2017 Aug 11. doi:10.15585/mmwr.mm6631a1
- Seiden LG, Connor GS. The importance of drug titration in the management of patients with epilepsy. *Epilepsy Behav*. 2022;128:108517. doi:10.1016/j.yebeh.2021.108517
- Williams B, Gidal BE, Resnick T, Baker J, Holtzman M, Spurling N, Maher J, Pleuschnat G. Influence of titration of antiseizure medications on treatment selection: Results of an online survey with clinicians in the United States. *Epilepsy Behav*. 2021;117:107840. doi:10.1016/j.yebeh.2021.107840
- Caffrey AR, Borrelli EP. The art and science of drug titration. *Ther Adv Drug Saf*. 2021;11:2042098620958910. Published 2021 Jan 19. doi:10.1177/2042098620958910

**ACKNOWLEDGEMENTS** The authors would like to thank Diane Ito, Josephine Li-McLeod, Ava Maurillo, and Brad Padilla from Stravati for their contributions to data analysis, medical writing, and editorial support of this poster. Xenon Pharmaceuticals reviewed and provided feedback on the poster. The authors had full editorial control of the poster and provided their final approval of all content.

**DISCLOSURES** JMS: Consultant and speaker for Ceribell, Jazz Pharmaceuticals, LivaNova, Neurelis, SK Life Science, UCB, and Xenon Pharmaceuticals (advisory board). DAB: Consultant and speaker for Jazz Pharmaceuticals, LivaNova, Neurelis, NeuroPace, SK Life Science, and Xenon Pharmaceuticals (advisory board). SSC: Speaker for Neurelis consultant and speaker for Jazz Pharmaceuticals, SK Life Science, UCB, and Xenon Pharmaceuticals (advisory board). MM: Consultant and speaker for Jazz Pharmaceuticals, SK Life Science, UCB, and Xenon Pharmaceuticals (advisory board). AJZ: Speaker for Jazz Pharmaceuticals and SK Life Science consultant and speaker for Catalyt, UCB, and Xenon Pharmaceuticals (advisory board). MZK: Speaker for SK Life Science and Xenon Pharmaceuticals (advisory board).

**FUNDING** This study was funded by Xenon Pharmaceuticals Inc.

